Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential

2. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Upside Potential as of April 28: 145.43%

Viking Global’s Stake Value: $179,348,324

Number of Hedge Fund Holders: 36

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is another biopharmaceutical company in Halvorsen’s portfolio with a high upside potential. The company develops treatments for cardiovascular diseases. Its main product is obicetrapib.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) reported $45.6 million Q4 2024 revenue, more than three times the figure in the same quarter in 2023. This growth was primarily driven by the achievement of a clinical success milestone and the recognition of revenue related to general development cost reimbursement. The company ended December 31, 2024, with cash and cash equivalents of $771.7 million and $62.5 million in marketable securities, up from $340.5 million at the end of 2023.

The firm’s regulatory and commercial progress continues to advance. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) expects its partner Menarini to submit for European marketing approval in the second half of 2025. At the same time, the company’s Phase 3 PREVAIL cardiovascular outcomes trial remains on track with over 9,500 patients enrolled. On April 17, 2025, Jefferies analyst Dennis Ding maintained a Buy rating on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) and set a price target of $45.00. The company’s shares currently trade at $17.52, close to their 52-week low of $14.06. This indicates a significant upside potential based on analyst expectations.